ArticleBritish journal of cancer2017
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Meng Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
49 papers cite it
this paperpooled itcites it